US 8,076,288 B2 · Hybrid polypeptides having glucose lowering activity

Abstract

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Claims7

Dependent claims

A hybrid polypeptide exhibiting at least two hormonal activities, said hybrid polypeptide comprising a first bio-active peptide hormone covalently linked to at least one additional bio-active peptide hormone, wherein:

the first bio-active peptide hormone is independently selected from the group consisting of:
exendin-4 and an exendin-4 analog;
the at least one additional bio-active peptide hormone is independently selected from the group consisting of:
amylin and an amylin analog;
each of the bio-active peptide hormones of the hybrid exhibits at least one hormonal activity of its parent peptide hormone;
and the hybrid polypeptide comprises the sequence SEQ ID NO:
33.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application

11/206,903Filed 17 Aug 2005 · continuation in part

Priority

11 Feb 2004

Published

US 2006/0094652 A128 Dec 2006

Granted

13 Dec 2011

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

C07K 14/605
Hormones: glucagons
C07K 5/1013
And aliphatic: the side chain containing O or S as heteroatoms, e.g. Cys, Ser
C07K 5/1024
Tetrapeptides: with the first amino acid being heterocyclic
C07K 14/575
From animals; from humans: hormones

Family

Application60/543,407Us provisional application · filed 11 Feb 2004

Application11/055,093Parent of this continuation-in-part · filed 11 Feb 2005

Application11/201,664Parent of this continuation-in-part · filed 11 Aug 2005

US 2006/0293232 A1Pre-grant publication · published 28 Dec 2006

US 2006/0094652 A1Published application

US 8,076,288 B2This patent

From the US filing history. Foreign family members aren’t listed.

Hybrid polypeptides having glucose lowering activity

Life of this patent

Hybrid polypeptides having glucose lowering activity

Life of this patent

Abstract

Claims7